secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001193125-24-127657
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants
--------------------------------------------------------------------------------

- 4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.
- Warrants exercisable at $4.68/share for 3 years; callable by Aileron after top-line LTI-03 Phase 1b results if VWAP exceeds exercise price.
- Net proceeds to fund LTI-03 Phase 1b trial, working capital; cash runway projected through Q2 2025.
- Offering closing on May 3, 2024; Titan Partners Group acted as sole book-runner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/0001193125-24-127657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/d811393d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-127657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer